By Connor Hart
Zscaler narrowed its loss and posted higher revenue in its fiscal 1Q, but its current-quarter outlook failed to impress investors. The cloud-security company guided for adjusted earnings between 68 cents a share and 69 cents a share, as well as revenue between $633 million and $635 million, both of which just met analyst expectations. Shares fall 7.8%, to $192.25, in after-hours trading.
Janux Therapeutics' prostate cancer treatment was selected for expansion trials following what the company called encouraging efficacy and safety results. The treatment, called JANX007, resulted in high prostate-specific antigen response rates and deep prostate-specific antigen declines across all doses in a Phase 1a clinical trial. Shares surge 58%, to $63.60, in post-market trading.
TransMedics lowered its full-year outlook. The Andover, Mass., medical-technology company now expects full-year revenue between $428 million and $432 million, down from its previous outlook of between $425 million and $445 million. Analysts surveyed by FactSet are looking for $431.9 million. Shares fall 9.1%, to $77.40, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 02, 2024 18:36 ET (23:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。